CHARLESTON, S.C.--(EON: Enhanced Online News)--Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the “Company”), announced today that it will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 9:30 AM EST. President and Chief Executive Officer, Mr. David A. Dodd will be presenting an updated overview of the Company, as well as meeting with investors.
Participants may access the live webcast via the Company’s website at www.aezsinc.com. A replay of the webcast will also be available on the Company’s website approximately one hour following the live webcast.
The 2017 Disruptive Growth & Healthcare Conference will offer the exclusive opportunity to discover life science companies focusing on solutions to unmet medical needs and growth companies with disruptive technologies and business models.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology. We are engaged in drug development activities and in the promotion of products for others. We are now conducting Phase 3 studies of two internally developed compounds. The focus of our business development efforts is the acquisition or in-license of products that are relevant to our therapeutic areas of focus. We also intend to license out certain commercial rights of internally developed products to licensees in territories where such out-licensing would enable us to ensure development, registration and launch of our product candidates. Our goal is to become a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of our product portfolio, achieving successful commercial presence and growth, while consistently delivering value to our shareholders, employees and the medical providers and patients who will benefit from our products. For more information, visit www.aezsinc.com.
For those interested in attending, please visit www.DisruptNYC.com for more information.